MDisrupt Webinar

Building digital health products that scale—why chief medical and scientific officers are the key to widespread adoption

Date: Tuesday, August 24, 2021
Time: 11:00AM – 12:00PM PST

Chief Medical Officers and Chief Scientific Officers are critical first hires for a digital health company. From accelerating your product’s path to market to ensuring your claims are bound by science and balancing consumer needs with medical integrity, CMOs and CSOs can be a founding team’s lifeboat.

In this webinar, we’ll cover:
  • A day in the life of a CMO or CSO in a digital health company
  • How CMOs and CSOs with varying backgrounds can play important roles in your business
  • The clash between the commercial mindset and medical responsibility
  • What happens when you don’t have a CMO or CSO from the start

Meet the Panelists

Chet Robson

Chet Robson DO, MHCDS, FAAFP (Moderator)

Chief Clinical Officer, Walgreens

Read Bio

Dr. Robson provides evidence-based leadership for pharmacy, specialty pharmacy, healthcare services, digital innovation and retail merchandising. He is the medical director of the Walgreens Pandemic Response and is leading the development of a healthcare destination that integrates primary care, pharmacy, and ancillary services (labs and digital resources) into the flow of people’s lives. He also leads Walgreens’ development of pharmacogenomics and clinical research. Dr. Robson holds an MBA in healthcare delivery science from Dartmouth.

Deena Shakir

Federico Monzon, MD

Strategy Consultant, Medical Genomics

Read Bio

Dr. Monzon is a molecular pathologist with expertise in clinical genomics, molecular diagnostics and pathology informatics. He was chief medical officer (CMO) at Castle Biosciences and is currently CMO at Universal Diagnostics. He has a strong track record of clinical lab innovation focused on translating novel genomic technologies into medicine. At the University of Pittsburgh, he led the clinical validation study supporting FDA clearance of one of the first gene expression tests using gene expression microarrays (Pathwork Tissue of Origin). Dr. Monzon has directed molecular diagnostics laboratories at Houston Methodist Hospital and at Baylor College of Medicine (BCM), where he oversaw the launch of the first NGS-based clinical cancer exome in the US. At Invitae, he led the oncology team, working closely with the commercial team on business strategy and medical affairs in Latin America.

Madhuri Hedge

Madhuri Hegde, PhD, DABMG, FACMG

SVP and Chief Scientific Officer, Global Lab Services at PerkinElmer, Inc.

Read Bio
Dr. Hegde is an adjunct professor of applied biology at Georgia Tech and previously served as executive director of Emory Genetics Laboratory and was professor of genetics and pediatrics at Emory University. Her clinical work focuses on high-throughput strategies for discovery and clinical testing for rare disorders, using next generation sequencing (NGS), robotics, clinical exome and genome sequencing, and oligonucleotide array platforms. Dr. Hegde has over 20 years’ experience in clinical diagnostics, and has extensive knowledge of CLIA, CAP, and NY regulations related to LDTs and NGS. She has served on several FDA panels related to NGS and other molecular technologies. She received a BSc and an MSc from the University of Bombay, and a PhD from the University of Auckland, New Zealand. She completed postdoctoral studies at Baylor College of Medicine.
Bernard Esquivel

Bernard Esquivel, MD, PhD

Precision Medicine Advocate & Executive Leader

Read Bio

Dr. Esquivel is a practicing physician-scientist, senior executive, and international business leader with expertise in developing new markets in genomics and precision medicine. As founder and president of ALAMP, he mobilized the regional healthcare community to engage in precision medicine. ALAMP now includes >400 members from nine Latin American countries and holds symposia, provider workshops, and other educational events.

Share This